期刊文献+

小鼠原位移植性肝癌模型的建立及其磁共振表现 被引量:6

Establishment of an orthotroqic tumor model for hepatocellular carcinoma and non-invasive in vivo tumor imaging by MRI in mice
暂未订购
导出
摘要 目的:建立一种小鼠原位移植性肝癌模型,观察其磁共振表现。方法:先建立H22腹水瘤小鼠模型,抽取癌性腹水,制备H22小鼠肝癌细胞悬液,然后开腹直视下分别将0.02ml的H22细胞悬液(5×10^5)注入20只BALB/c小鼠的肝实质内。MRI观察肿瘤体积及其影像学表现,取肿瘤标本行病理学检查。留取10只荷瘤小鼠观察自然生存期。结果:肝的原位成瘤率为100%(20/20),肿瘤自发消退率为0(0/20),荷瘤小鼠自然生存期为18~28天,平均为21.7±1.1天。MRI检查:术后7天肿瘤平均体积为(7.76±1.33)mm^3;术后14天肿瘤平均体积为(126.31±42.03)mm^3;肿瘤病灶在T1WI上呈低信号或等信号,在T2WI上呈高信号。病理切片证实肝脏成瘤。结论:成功建立BALB/c小鼠原位移植性肝癌模型;MRI是一种可用于发现、追踪小鼠原位移植性肝癌模型的无创监测手段。 Objective: To establish an orthotropic tumor model for hepatocellular carcinoma in mice and study its MRI features. Methods: 5 × 10^5 H22 hepatoma cells were injected into the liver of 20 BALB/c mice. MRI was performed on the 7th, 14th day after injection for analyzing the tumor growth and its characters. The tumor specimens were taken out for pathological examination. Survival rates were observed in 10 mice. Results : The successful rate of model was 100% (20/20), the natural extinctive rate was 0(0/20), and the survival time ranged from 18 days to 28 days, mean survival time was 21.7 ± 1.1 days. Mean tumor volume was 7.76 ± 1.33mm3 on the 7th day, 126.31 ± 42.03mm3 on the 14th day after injection. The tumors were hypointense on T1 WI and hyperintense on T2WI. Tumor estabhshment was confirmed histologically in liver sections. Conclusion: H22 hepatoma ceils are suitable for the establishment of orthotropic liver tumors in BALB/c mice. MRI is a tool for the non - invasive assessment of tumor diagnosis and tumor growth in this model.
出处 《现代肿瘤医学》 CAS 2007年第2期174-176,共3页 Journal of Modern Oncology
关键词 肝癌 小鼠 疾病模型 动物 核磁共振成像 hepatocellular carcinoma mice disease models animal magnetic resonance imaging
  • 相关文献

参考文献5

二级参考文献20

共引文献72

同被引文献40

  • 1黄连玉,郭兆平.谈中药在治疗恶性肿瘤中的作用[J].中国中医药杂志,2005,3(6):763-764. 被引量:8
  • 2陈雨凤,张少华.活血化瘀药抗肿瘤及肿瘤转移的作用机理探讨[J].陕西中医学院学报,2006,29(2):62-63. 被引量:21
  • 3姚登福,苏小琴.肝细胞核因子-κB异常激活与肝细胞癌变[J].中华肝脏病杂志,2006,14(7):539-540. 被引量:9
  • 4曹雪涛.肿瘤生长与转移中的免疫学问题[J].中国肿瘤生物治疗杂志,2007,14(1):2-6. 被引量:24
  • 5Rodriguez PC,Hernandez CP,Quiceno D,et al. Arginase Ⅰ in myeloid suppressor cells is induced by COX-2 in lung carcinoma. J Exp Med, 2005,202:931-939.
  • 6Bronte V,Apolloni E,Cabrelle A, et al. Identification of a CD11b^+/ Gr-Ⅰ^+/CD31^+ myeloid progenitor capable of activating or suppressing CD8^+T cells. Blood,2000,96:3838-3846.
  • 7Capuano G, Rigamonti N,Grioni M,et al. Modulators of arginine metabolism support cancer immunosurveillance. BMC Immunol, 2009, 10:1-36.
  • 8Li HQ,Han YM,Guo QL,et al. Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1. J Immunol, 2009,182 ( 1 ):240-249.
  • 9Ochoa AC,Zea AH,Hernandez C et al. Arginase,prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma. Clin Cancer Res,2007,13(2 Pt 2):721s-726s.
  • 10Serafini P,Borrello I,Bronte V. Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin Cancer Biol,2006,16:53-65.

引证文献6

二级引证文献33

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部